Research Article
Radiation Dose-Effect Relation in Patients with Esophageal Squamous Cell Carcinoma: A National Cancer Center Data and Literature-Based Analysis
Table 1
Baseline characteristics.
| | Characteristics | No. (%) |
| | Age | <70 years | 1017 (70.63%) | | ≥70 years | 423 (29.37%) | | Median (range)(years) | 63 (33–89) |
| | Sex | Male | 1178 (81.81%) | | Female | 262 (18.19%) |
| | KPS | <80 | 152 (10.56%) | | ≥80 | 1288 (89.44%) |
| | T Stage (AJCC 6th) | T1 | 32 (2.22%) | | T2 | 147 (10.21%) | | T3 | 622 (43.19%) | | T4 | 639 (44.38%) |
| | N stage (AJCC 6th) | N0 | 214 (14.86%) | | N1 | 1226 (85.14%) |
| | M stage (AJCC 6th) | M0 | 1046 (72.64%) | | M1a | 145 (10.07%) | | M1b | 249 (17.29%) |
| | TNM stage (AJCC 6th) | Stage IIA | 121 (8.40%) | | Stage IIB | 90 (6.25%) | | Stage III | 835 (57.99%) | | Stage IVA | 145 (10.07%) | | Stage IVB | 249 (17.29%) |
| | Tumor location | Upper third | 502 (34.86%) | | Middle third | 689 (47.85%) | | Lower third | 249 (17.29%) |
| | Radiation technique | 3D-CRT | 118 (8.19%) | | IMRT | 1225 (85.07%) | | VMAT | 97 (6.74%) |
| | Radiation dose (EQD2) | ≥40 Gy, < 50 Gy | 88 (6.11%) | | ≥50 Gy, < 60 Gy | 270 (18.75%) | | ≥60 Gy, < 66 Gy | 988 (68.61%) | | ≥66 Gy, < 70 Gy | 74 (5.14%) | | 70 Gy | 20 (1.39%) | | Median(range)(Gy) | 60 (40–70) |
| | Induction chemotherapy | No | 1353 (93.96%) | | Yes | 87 (6.04%) |
| | Concurrent chemotherapy | No | 781 (54.24%) | | Yes | 659 (45.76%) |
|
|
KPS = Karnofsky performance status, EQD2 = equivalent dose in 2 Gy per fraction, 3D-CRT = 3-dimensional conformal radiotherapy, IMRT = intensity-modulated radiotherapy, and VMAT = volumetric modulated arc therapy. |
